{"result": {"id": "6d22027e-dfe8-4cdd-a9df-21f5ed841e59", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>OKIN PM<|>PERSON<|>Researcher involved in the LIFE study on electrocardiographic strain patterns\")\n##\n(\"entity\"<|>OIKARINEN L<|>PERSON<|>Researcher involved in the LIFE study on electrocardiographic strain patterns\")\n##\n(\"entity\"<|>VIITASALO M<|>PERSON<|>Researcher involved in the LIFE study on electrocardiographic strain patterns\")\n##\n(\"entity\"<|>ZONG WENYI<|>PERSON<|>Researcher involved in the Chinese study on irbesartan for type 2 diabetes\")\n##\n(\"entity\"<|>YANG WENYING<|>PERSON<|>Researcher involved in the Chinese study on irbesartan for type 2 diabetes\")\n##\n(\"entity\"<|>XIANG HONGDING<|>PERSON<|>Researcher involved in the Chinese study on irbesartan for type 2 diabetes\")\n##\n(\"entity\"<|>LIU L<|>PERSON<|>Researcher involved in the FEVER study on Chinese hypertensive patients\")\n##\n(\"entity\"<|>ZHANG Y<|>PERSON<|>Researcher involved in the FEVER study on Chinese hypertensive patients\")\n##\n(\"entity\"<|>LIU G<|>PERSON<|>Researcher involved in the FEVER study on Chinese hypertensive patients\")\n##\n(\"entity\"<|>WANG WEN<|>PERSON<|>Researcher involved in the Chinese hypertension treatment study\")\n##\n(\"entity\"<|>MA LIYUAN<|>PERSON<|>Researcher involved in the Chinese hypertension treatment study\")\n##\n(\"entity\"<|>LIU MINGBO<|>PERSON<|>Researcher involved in the Chinese hypertension treatment study\")\n##\n(\"entity\"<|>FRANKLIN SS<|>PERSON<|>Researcher involved in the Framingham Heart Study\")\n##\n(\"entity\"<|>LOPEZ VA<|>PERSON<|>Researcher involved in the Framingham Heart Study\")\n##\n(\"entity\"<|>WONG ND<|>PERSON<|>Researcher involved in the Framingham Heart Study\")\n##\n(\"entity\"<|>ZHENG L<|>PERSON<|>Researcher studying blood pressure and cardiovascular events\")\n##\n(\"entity\"<|>LI J<|>PERSON<|>Researcher studying blood pressure and cardiovascular events\")\n##\n(\"entity\"<|>SUN Z<|>PERSON<|>Researcher studying blood pressure and cardiovascular events\")\n##\n(\"relationship\"<|>OKIN PM<|>LOSARTAN INTERVENTION FOR END-POINT REDUCTION IN HYPERTENSION STUDY (LIFE)<|>Okin PM was involved in the LIFE study<|>7\")\n##\n(\"relationship\"<|>OIKARINEN L<|>LOSARTAN INTERVENTION FOR END-POINT REDUCTION IN HYPERTENSION STUDY (LIFE)<|>Oikarinen L was involved in the LIFE study<|>7\")\n##\n(\"relationship\"<|>VIITASALO M<|>LOSARTAN INTERVENTION FOR END-POINT REDUCTION IN HYPERTENSION STUDY (LIFE)<|>Viitasalo M was involved in the LIFE study<|>7\")\n##\n(\"relationship\"<|>ZONG WENYI<|>IRBESARTAN<|>Zong Wenyi studied irbesartan for type 2 diabetes<|>7\")\n##\n(\"relationship\"<|>YANG WENYING<|>IRBESARTAN<|>Yang Wenying studied irbesartan for type 2 diabetes<|>7\")\n##\n(\"relationship\"<|>XIANG HONGDING<|>IRBESARTAN<|>Xiang Hongding studied irbesartan for type 2 diabetes<|>7\")\n##\n(\"relationship\"<|>LIU L<|>FELODIPINE EVENT REDUCTION (FEVER) STUDY<|>Liu L was involved in the FEVER study<|>7\")\n##\n(\"relationship\"<|>ZHANG Y<|>FELODIPINE EVENT REDUCTION (FEVER) STUDY<|>Zhang Y was involved in the FEVER study<|>7\")\n##\n(\"relationship\"<|>LIU G<|>FELODIPINE EVENT REDUCTION (FEVER) STUDY<|>Liu G was involved in the FEVER study<|>7\")\n##\n(\"relationship\"<|>WANG WEN<|>CHINESE HYPERTENSION TREATMENT STUDY<|>Wang Wen was involved in the Chinese hypertension treatment study<|>7\")\n##\n(\"relationship\"<|>MA LIYUAN<|>CHINESE HYPERTENSION TREATMENT STUDY<|>Ma Liyuan was involved in the Chinese hypertension treatment study<|>7\")\n##\n(\"relationship\"<|>LIU MINGBO<|>CHINESE HYPERTENSION TREATMENT STUDY<|>Liu Mingbo was involved in the Chinese hypertension treatment study<|>7\")\n##\n(\"relationship\"<|>FRANKLIN SS<|>FRAMINGHAM HEART STUDY<|>Franklin SS was involved in the Framingham Heart Study<|>7\")\n##\n(\"relationship\"<|>LOPEZ VA<|>FRAMINGHAM HEART STUDY<|>Lopez VA was involved in the Framingham Heart Study<|>7\")\n##\n(\"relationship\"<|>WONG ND<|>FRAMINGHAM HEART STUDY<|>Wong ND was involved in the Framingham Heart Study<|>7\")\n##\n(\"relationship\"<|>ZHENG L<|>BLOOD PRESSURE AND CARDIOVASCULAR EVENTS STUDY<|>Zheng L studied blood pressure and cardiovascular events<|>7\")\n##\n(\"relationship\"<|>LI J<|>BLOOD PRESSURE AND CARDIOVASCULAR EVENTS STUDY<|>Li J studied blood pressure and cardiovascular events<|>7\")\n##\n(\"relationship\"<|>SUN Z<|>BLOOD PRESSURE AND CARDIOVASCULAR EVENTS STUDY<|>Sun Z studied blood pressure and cardiovascular events<|>7\")\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752165627, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1372, "prompt_tokens": 4740, "total_tokens": 6112, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 4672}, "prompt_cache_hit_tokens": 4672, "prompt_cache_miss_tokens": 68}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: :10.1056/NEJMoa0801369.\n[23]  Okin  PM,Oikarinen  L,Viitasalo  M,et  al.Prognostic  value  of changes  in  the  electrocardiographic  strain  pattern  during antihypertensive   treatment:the    Losartan    Intervention   for End-Point   Reduction    in   Hypertension    Study    (LIFE)[J]. Circulation,2009,119(14):1883-1891.DOI:10.1161                  / CIRCULATIONAHA.108.812313.\n[24]     Parving    HH,Lehnert    H,Brochner-Mortensen    J,et    al.The effect   of   irbesartan    on    the    development    of   diabetic nephropathy in patients with type 2 diabetes[J].N EnglJ Med, 2001,345(12):870-878.DOI:10.1056/NEJMoa011489.\n[25]  宗文漪，杨文英，向红丁，等.厄贝沙坦治疗2型糖尿病伴 白蛋白尿患者有效性和安全性：多中心随机双盲对照研究 [J]. 中华内分泌代谢杂志，2008,24(1):55-58.DOI:10.3321/j.  issn:1000-6699.2008.01.016.\n[26]  Lewis    EJ,Hunsicker   LG,Clarke    WR,et   al.Renoprotective ffect  of  the   angiotensin-receptor   antagonist   irbesartan  in patients with nephropathy due to type 2 diabetes[J].N Engl J Med,2001,345(12):851-860.DOI:10.1056/NEJMoa011303.\n[27]  Liu  L,Zhang  Y,Liu  G,et  al.The Felodipine Event Reduction (FEVER)Study:a  randomized  long-term  placebo-controlled trial in Chinese hypertensive patients[J].J Hypertens,2005,23 (12):2157-2172.\n[28]  中华医学会心血管病学分会高血压学组.清晨血压临床管 理的中国专家指导建议[J].中华心血管病杂志，2014,42(9): 721-725.DOI:10.3760/cma.j.issn.0253-3758.2014.09.003.\n[29]  Brown    MJ.Palmer   CR,Castaigne   A,et    al.Morbidity    and mortality  in  patients  randomised  to  double-blind  treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study:Intervention as a Goal in Hypertension     Treatment     (INSIGHT)[J].Lancet,2000,356 (9227):366-372.DOI:10.1016/S0140-6736(00)02527-7.\n[30]     Kario  K,Saito  I,Kushiro  T,et  al.Home  blood  pressure  and cardiovascular outcomes in patients during  antihypertensive therapy:primary      results      of      HONEST,a      large-scale prospective,real-world   observational   study[J].Hypertension, 2014,64(5):989-996.DOI:10.1161/HYPERTENSIONAHA.\n114.04262.\n[31]     Weber    MA,Julius    S,Kjeldsen    SE,et    al.Blood    pressure  dependent   and   independent    effects    of   antihypertensive treatment on clinical  events in the VALUE Trial[J].Lancet, 2004,363(9426):2049-2051.DOI:10.1016/S0140-6736(04)\n16456-8.\n[32]  王文，马丽媛，刘明波，等.初始低剂量氨氯地平加替米沙坦 或复方阿米洛利联合治疗对高血压患者血压控制率影响 的阶段报告[J].中华心血管病杂志，2009,25(8):701-707.DOI: 10.3760/cma.j.issn.0253-3758.2009.08.007.\n[33]     Franklin    SS,Lopez    VA.Wong    ND,et    al.Single    versus combined    blood    pressure    components    and    risk    for cardiovascular   disease:the   Framingham   Heart    Study   [J].\nCirculation,2009,119(2):243-250.DOI:                   10.1161     /\nCIRCULATIONAHA.108.797936.\n[34]  Zheng   L,Li  J,Sun  Z,et   al.Relationship  of  Blood  Pressure With    Mortality     and     Cardiovascular    Events    Among Hypertensive\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>LOSARTAN INTERVENTION FOR END-POINT REDUCTION IN HYPERTENSION STUDY (LIFE)<|>EVENT<|>A study evaluating the prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment\")\n##\n(\"entity\"<|>CIRCULATION<|>ORGANIZATION<|>A journal that published the LIFE study results\")\n##\n(\"entity\"<|>PARVING HH<|>PERSON<|>Researcher involved in the study on the effect of irbesartan on diabetic nephropathy\")\n##\n(\"entity\"<|>LEHNERT H<|>PERSON<|>Researcher involved in the study on the effect of irbesartan on diabetic nephropathy\")\n##\n(\"entity\"<|>BROCHNER-MORTENSEN J<|>PERSON<|>Researcher involved in the study on the effect of irbesartan on diabetic nephropathy\")\n##\n(\"entity\"<|>IRBESARTAN<|>ORGANIZATION<|>A medication studied for its effect on diabetic nephropathy\")\n##\n(\"entity\"<|>N ENGL J MED<|>ORGANIZATION<|>A journal that published the study on irbesartan and diabetic nephropathy\")\n##\n(\"entity\"<|>LEWIS EJ<|>PERSON<|>Researcher involved in the study on the renoprotective effect of irbesartan\")\n##\n(\"entity\"<|>HUNSICKER LG<|>PERSON<|>Researcher involved in the study on the renoprotective effect of irbesartan\")\n##\n(\"entity\"<|>CLARKE WR<|>PERSON<|>Researcher involved in the study on the renoprotective effect of irbesartan\")\n##\n(\"entity\"<|>FELODIPINE EVENT REDUCTION (FEVER) STUDY<|>EVENT<|>A randomized long-term placebo-controlled trial in Chinese hypertensive patients\")\n##\n(\"entity\"<|>J HYPERTENS<|>ORGANIZATION<|>A journal that published the FEVER study results\")\n##\n(\"entity\"<|>BROWN MJ<|>PERSON<|>Researcher involved in the INSIGHT study\")\n##\n(\"entity\"<|>PALMER CR<|>PERSON<|>Researcher involved in the INSIGHT study\")\n##\n(\"entity\"<|>CASTAGNE A<|>PERSON<|>Researcher involved in the INSIGHT study\")\n##\n(\"entity\"<|>INTERNATIONAL NIFEDIPINE GITS STUDY: INTERVENTION AS A GOAL IN HYPERTENSION TREATMENT (INSIGHT)<|>EVENT<|>A study comparing long-acting calcium-channel blocker or diuretic treatment in hypertension\")\n##\n(\"entity\"<|>LANCET<|>ORGANIZATION<|>A journal that published the INSIGHT study results\")\n##\n(\"entity\"<|>KARIO K<|>PERSON<|>Researcher involved in the HONEST study\")\n##\n(\"entity\"<|>SAITO I<|>PERSON<|>Researcher involved in the HONEST study\")\n##\n(\"entity\"<|>KUSHIRO T<|>PERSON<|>Researcher involved in the HONEST study\")\n##\n(\"entity\"<|>HONEST<|>EVENT<|>A large-scale prospective, real-world observational study on home blood pressure and cardiovascular outcomes\")\n##\n(\"entity\"<|>HYPERTENSION<|>ORGANIZATION<|>A journal that published the HONEST study results\")\n##\n(\"entity\"<|>WEBER MA<|>PERSON<|>Researcher involved in the VALUE Trial\")\n##\n(\"entity\"<|>JULIUS S<|>PERSON<|>Researcher involved in the VALUE Trial\")\n##\n(\"entity\"<|>KJELDSEN SE<|>PERSON<|>Researcher involved in the VALUE Trial\")\n##\n(\"entity\"<|>VALUE TRIAL<|>EVENT<|>A trial studying blood pressure dependent and independent effects of antihypertensive treatment on clinical events\")\n##\n(\"entity\"<|>FRAMINGHAM HEART STUDY<|>EVENT<|>A study on single versus combined blood pressure components and risk for cardiovascular disease\")\n##\n(\"relationship\"<|>LOSARTAN INTERVENTION FOR END-POINT REDUCTION IN HYPERTENSION STUDY (LIFE)<|>CIRCULATION<|>The LIFE study results were published in the Circulation journal<|>8\")\n##\n(\"relationship\"<|>PARVING HH<|>IRBESARTAN<|>Parving HH studied the effect of irbesartan on diabetic nephropathy<|>7\")\n##\n(\"relationship\"<|>LEHNERT H<|>IRBESARTAN<|>Lehnert H studied the effect of irbesartan on diabetic nephropathy<|>7\")\n##\n(\"relationship\"<|>BROCHNER-MORTENSEN J<|>IRBESARTAN<|>Brochner-Mortensen J studied the effect of irbesartan on diabetic nephropathy<|>7\")\n##\n(\"relationship\"<|>IRBESARTAN<|>N ENGL J MED<|>The study on irbesartan and diabetic nephropathy was published in the N Engl J Med journal<|>8\")\n##\n(\"relationship\"<|>LEWIS EJ<|>IRBESARTAN<|>Lewis EJ studied the renoprotective effect of irbesartan<|>7\")\n##\n(\"relationship\"<|>HUNSICKER LG<|>IRBESARTAN<|>Hunsicker LG studied the renoprotective effect of irbesartan<|>7\")\n##\n(\"relationship\"<|>CLARKE WR<|>IRBESARTAN<|>Clarke WR studied the renoprotective effect of irbesartan<|>7\")\n##\n(\"relationship\"<|>FELODIPINE EVENT REDUCTION (FEVER) STUDY<|>J HYPERTENS<|>The FEVER study results were published in the J Hypertens journal<|>8\")\n##\n(\"relationship\"<|>BROWN MJ<|>INTERNATIONAL NIFEDIPINE GITS STUDY: INTERVENTION AS A GOAL IN HYPERTENSION TREATMENT (INSIGHT)<|>Brown MJ was involved in the INSIGHT study<|>7\")\n##\n(\"relationship\"<|>PALMER CR<|>INTERNATIONAL NIFEDIPINE GITS STUDY: INTERVENTION AS A GOAL IN HYPERTENSION TREATMENT (INSIGHT)<|>Palmer CR was involved in the INSIGHT study<|>7\")\n##\n(\"relationship\"<|>CASTAGNE A<|>INTERNATIONAL NIFEDIPINE GITS STUDY: INTERVENTION AS A GOAL IN HYPERTENSION TREATMENT (INSIGHT)<|>Castagne A was involved in the INSIGHT study<|>7\")\n##\n(\"relationship\"<|>INTERNATIONAL NIFEDIPINE GITS STUDY: INTERVENTION AS A GOAL IN HYPERTENSION TREATMENT (INSIGHT)<|>LANCET<|>The INSIGHT study results were published in the Lancet journal<|>8\")\n##\n(\"relationship\"<|>KARIO K<|>HONEST<|>Kario K was involved in the HONEST study<|>7\")\n##\n(\"relationship\"<|>SAITO I<|>HONEST<|>Saito I was involved in the HONEST study<|>7\")\n##\n(\"relationship\"<|>KUSHIRO T<|>HONEST<|>Kushiro T was involved in the HONEST study<|>7\")\n##\n(\"relationship\"<|>HONEST<|>HYPERTENSION<|>The HONEST study results were published in the Hypertension journal<|>8\")\n##\n(\"relationship\"<|>WEBER MA<|>VALUE TRIAL<|>Weber MA was involved in the VALUE Trial<|>7\")\n##\n(\"relationship\"<|>JULIUS S<|>VALUE TRIAL<|>Julius S was involved in the VALUE Trial<|>7\")\n##\n(\"relationship\"<|>KJELDSEN SE<|>VALUE TRIAL<|>Kjeldsen SE was involved in the VALUE Trial<|>7\")\n##\n(\"relationship\"<|>FRAMINGHAM HEART STUDY<|>CIRCULATION<|>The Framingham Heart Study results were published in the Circulation journal<|>8\")\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_ba36527cfa82858c939e563dc02adec32ba998ff568d64e7cb962c4cdec8ce73_v2"}